STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease

The Food and Drug Administration on Thursday approved a new gene therapy for Sanfilippo syndrome type A, an ultra-rare disease sometimes known as childhood Alzheimer’s. The therapy, called Fayuvi, was developed by Ultragenyx. It is the first drug…

Read the full story at STAT ↗